Axsome Therapeutics (AXSM) Assets (2015 - 2026)

Axsome Therapeutics (AXSM) has 12 years of Assets data on file, last reported at $713.6 million in Q1 2026.

• For the quarter ending Q1 2026, Assets rose 19.6% year-over-year to $713.6 million; the trailing twelve-month figure through Mar 2026 stood at $713.6 million (up 19.6% YoY), and the FY2025 full-year result was $689.8 million, up 21.34% from the prior year.
• Assets improved to $713.6 million in Q1 2026, from $689.8 million in the prior quarter.
• In the past five years, Assets ranged from a high of $713.6 million in Q1 2026 to a low of $88.6 million in Q1 2022.
• A 5-year average of $509.6 million and a median of $568.5 million in 2024 frame the typical range for Assets.
• Across the five-year window, Assets plunged 46.94% in 2022 and surged 339.45% in 2023, its largest moves.
• Tracing AXSM's Assets over 5 years: stood at $331.5 million in 2022, then jumped by 77.46% to $588.2 million in 2023, then fell by 3.36% to $568.5 million in 2024, then increased by 21.34% to $689.8 million in 2025, then rose by 3.45% to $713.6 million in 2026.
• Business Quant data shows AXSM's Assets at $713.6 million in Q1 2026, $689.8 million in Q4 2025, and $669.2 million in Q3 2025.